Navigation Links
Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Date:10/22/2007

SANTA MONICA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an update on its testing of Rh-Apo2L, the next large-scale product to be launched by the Company into the China market. Aida previously announced that it had successfully passed its Phase I tests in July 2006, which consists of tests for safety, dosage and the potential cancer treatments to be tested in Phases II & III. Aida is currently undergoing Phase II testing of Rh-Apo2L testing through China's SFDA, the national drug regulatory agency.

Phase II is divided into two substages: IIA and IIB. IIA consists of tests on over 100 human patients using only Rh-Apo2L and gauges the efficacy of the drug as well as the narrowing of the scope of targeted cancers. Results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer. Shanghai Qiaer, Aida's research subsidiary, has reduced the key cancer targets to the three main diseases which Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date, pending successful trials. Formal results will also be released after clinical tests are completed.

Phase IIB is testing Rh-Apo2L in combination with other anti-cancer drugs on the above three chosen diseases. The tests monitor interaction with other drugs, side effects and dosages for additional tests. To date, the combined use of Rh-Apo2L with selected anti-cancer drugs has shown good efficacy, reliable safety and no additional side effects. Tests are still ongoing for various dosage amounts on different types of cancer and no regulatory approval has been received for these drugs.

About Rh-Apo2L -- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. What patients want: A story of choice, clinical trials & evidence-based medicine
3. ZyStor seeks to raise $15M for clinical trials
4. Prodesse begins clinical trials for flu virus detection
5. ConjuGon raises $3.3 million to fund clinical trials
6. Cancer-fighting agent heads for clinical trials
7. Quintessence cancer treatment chosen for clinical studies
8. Third Wave reports clinical growth, continued loss
9. Childrens expanding use of Sunrise Clinical Manager
10. Life-sciences conference to feature novel research with clinical potential
11. $14 million grant to drive clinical research at UW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... SAN FRANCISCO, Calif., March 11 Raven,biotechnologies, inc., ... development of monoclonal antibody therapeutics (MAbs) for cancer,today ... RAV12 Phase,1/2a trial has been accepted as a ... the American Society of Clinical Oncology (ASCO).,The presentation ...
... in Western Pennsylvania Earn Designation, PITTSBURGH, March ... Allegheny General Hospital, UPMC Presbyterian Shadyside and UPMC,Passavant ... Cancers., Complex and rare cancers comprise approximately ... it difficult for patients to locate or,research facilities ...
... Ltd. has announced,development of a chemically synthesized vaccine ... its patented Replikins(TM) technology.,When the vaccine was administered ... lethal Taura virus. The specificity of the protective,effect ... the active,regions in the vaccine, and as a ...
Cached Biology Technology:Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 2Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 3Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2
(Date:8/31/2014)... release is available in French . ... study just published in the prestigious Nature Neuroscience ... Research Centre of the Douglas Mental Health University Institute and ... neural circuitry and dynamic mechanisms controlling memory as well of ... a sub-region named the subiculum. , In 2009, they ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
(Date:8/29/2014)... of connections in transcription factor networks (TFNs) to evaluate ... published in PLOS Computational Biology in August. ... to a network,s resilience against mutations. , "In ... TFN models has a greater effect on robustness than ... said Dov A. Pechenick, PhD, lead author and former ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
... 26, 2010) Consumption of 100 percent fruit juice ... diet quality in children and teens, according to new ... meeting. Two new studies from researchers at the ... Medicine clearly highlight the benefits of drinking 100 percent ...
... On April 15, 2010 , Dr. Stipkala joined a panel ... hosted by the University of South Carolina ,s NanoCenter in ... capitalists from all over the Southeast who are active in the nanotechnology ... Dr. Stipkala and ...
... YELLOWKNIFE, NT APRIL 2010 High in the Mackenzie ... tools being revealed as warming temperatures melt patches of ice ... Tom Andrews, an archaeologist with the Prince of Wales ... International Polar Year Ice Patch Study, is amazed at the ...
Cached Biology News:Drinking 100 percent fruit juice is associated with improved diet quality in children 2Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel 2Ancient artifacts reveals as northern ice patches melt 2
... DEPC-treated Water is suitable ... is prepared by incubating with ... autoclaved to remove the DEPC.DNase/RNase-Free ... for use in all molecular ...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: